Advertisement
Canada markets open in 17 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7301
    -0.0000 (-0.00%)
     

  • CRUDE OIL

    81.29
    -0.61 (-0.74%)
     

  • Bitcoin CAD

    90,584.80
    -66.33 (-0.07%)
     

  • CMC Crypto 200

    1,421.83
    +7.07 (+0.50%)
     

  • GOLD FUTURES

    2,324.20
    -22.20 (-0.95%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6460
    +0.0230 (+0.50%)
     

  • NASDAQ futures

    17,416.50
    +66.50 (+0.38%)
     

  • VOLATILITY

    16.51
    -0.43 (-2.54%)
     

  • FTSE

    8,037.33
    +13.46 (+0.17%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6841
    -0.0009 (-0.13%)
     
MARKETS LIVE BLOG:

STOCK FUTURES CLIMB AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

CooperCompanies Announces Release Date for Second Quarter 2023

CooperCompanies
·1 min read
CooperCompanies
CooperCompanies

SAN RAMON, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it will report second quarter 2023 financial results on Thursday, June 1, 2023, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7116518. A simultaneous audio webcast can be accessed on CooperCompanies’ investor relations website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com